SGLT2 Inhibitors in Cardio-Kidney-Metabolic Disease: Evidence, Guidelines, and Practice
Please check back later for more content.
Advertisement
Advertisement
Trending on AJMC
1
Tozorakimab Curbs Multiple COPD Inflammatory Pathways, ERS Data Show
2
Fragmented Care, Financial Strain, Gender Gaps Define Life With COPD
3
FDA Approves Camizestrant for ER+, HER2– mBC With ESR1 Mutations
4
AI Model Flags Colorectal Cancer on Routine Noncontrast CT Scans
5